One thing I forgot to add, and for me its basically on a par with wanting to know the full details on the trial.  That of course is the financial side. 

What we know, based on the most recent MD&A, is that Resverlogix does not have the required cash to meet all of its obligations through to the end of this year, unless there's has been some material change in the company's fiancial situtation that we don't know about. 

From page 17

As at July 31, 2019, we had $7.4 million of cash. We need to fund research, development and corporate activites within the next year. As at July 31, 2019, we were committed to pay $7.8 million of trade and other payables and $7.5 million for research and development. Furthermore, our $11.5 million loan with Third Eye is due on September 27, 2019. We are required to pay a further $0.7 million to Third Eye related to interest and other payments on or before the loan’s maturity. In addition, aggregate expenditures over the next twelve months under agreements with contract research organizations and central laboratories conducting the BETonMACE and other trials are estimated to total up to approximately $9 – 12 million.  

I know they got somewhere around $3 million from Eastern for the warrant conversion....but unless my math skills are way off they don't have anywhere near cash needed to meet their obligations over the next 3 months.  More stuff to speculate about.